737 related items for PubMed ID: 16501587
1. Cyclophosphamide, etoposide and carboplatine plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed non-Hodgkin's lymphomas.
Mabed M, Al-Kgodary T.
Bone Marrow Transplant; 2006 Apr; 37(8):739-43. PubMed ID: 16501587
[Abstract] [Full Text] [Related]
2. High-dose chemotherapy plus non-cryopreserved autologous peripheral blood stem cell transplantation rescue for patients with refractory or relapsed Hodgkin disease.
Mabed M, Shamaa S.
Biol Blood Marrow Transplant; 2006 Sep; 12(9):942-8. PubMed ID: 16920560
[Abstract] [Full Text] [Related]
3. High-dose chemotherapy with carboplatin, etoposide and ifosfamide followed by autologous stem cell rescue in patients with relapsed or refractory malignant lymphomas: a phase I/II study.
Kleiner S, Kirsch A, Schwaner I, Kingreen D, Schwella N, Huhn D, Siegert W.
Bone Marrow Transplant; 1997 Dec; 20(11):953-9. PubMed ID: 9422474
[Abstract] [Full Text] [Related]
4. Phase I/II study of high-dose cyclophosphamide, etoposide and cisplatin followed by autologous bone marrow or peripheral blood stem cell transplantation in patients with poor prognosis Hodgkin's disease or non-Hodgkin's lymphoma.
Klumpp TR, Mangan KF, Glenn LD, Malaspina DR, Cropper T, Mullaney M, Macdonald JS.
Bone Marrow Transplant; 1993 Oct; 12(4):337-45. PubMed ID: 7506091
[Abstract] [Full Text] [Related]
5. High-dose therapy with peripheral blood progenitor cell transplantation in low-grade non-Hodgkin's lymphoma.
Haas R, Moos M, Möhle R, Döhner H, Witt B, Goldschmidt H, Murea S, Flentje M, Wannenmacher M, Hunstein W.
Bone Marrow Transplant; 1996 Feb; 17(2):149-55. PubMed ID: 8640159
[Abstract] [Full Text] [Related]
6. A novel high-dose chemotherapy protocol with autologous hematopoietic rescue in patients with metastatic breast cancer or recurrent non-Hodgkin's lymphoma.
Fontelonga A, Kelly AJ, MacKintosh FR, Hall S, Monroe P, Wilson GS, Shaft D, Ruthven A, Ascensao JL.
Bone Marrow Transplant; 1997 May; 19(10):983-8. PubMed ID: 9169642
[Abstract] [Full Text] [Related]
7. Randomized trial of peripheral blood progenitor cell vs bone marrow as hematopoietic support for high-dose chemotherapy in patients with non-Hodgkin's lymphoma and Hodgkin's disease: a clinical and molecular analysis.
Kanteti R, Miller K, McCann J, Roitman D, Morelli J, Hurley C, Berkman E, Schenkein D.
Bone Marrow Transplant; 1999 Sep; 24(5):473-81. PubMed ID: 10482930
[Abstract] [Full Text] [Related]
8. High-dose carmustine, etoposide, and cisplatin for autologous stem cell transplantation with or without involved-field radiation for relapsed/refractory lymphoma: an effective regimen with low morbidity and mortality.
Wadhwa PD, Fu P, Koc ON, Cooper BW, Fox RM, Creger RJ, Bajor DL, Bedi T, Laughlin MJ, Payne J, Gerson SL, Lazarus HM.
Biol Blood Marrow Transplant; 2005 Jan; 11(1):13-22. PubMed ID: 15625540
[Abstract] [Full Text] [Related]
9. Ifosfamide, etoposide, cytarabine, and dexamethasone as salvage treatment followed by high-dose cyclophosphamide, melphalan, and etoposide with autologous peripheral blood stem cell transplantation for relapsed or refractory lymphomas.
Schütt P, Passon J, Ebeling P, Welt A, Müller S, Metz K, Moritz T, Seeber S, Nowrousian MR.
Eur J Haematol; 2007 Feb; 78(2):93-101. PubMed ID: 17313557
[Abstract] [Full Text] [Related]
10. Activity of interleukin-2 in non-Hodgkin's lymphoma following transplantation of interleukin-2-activated autologous bone marrow or stem cells.
van Besien K, Margolin K, Champlin R, Forman S.
Cancer J Sci Am; 1997 Dec; 3 Suppl 1():S54-8. PubMed ID: 9457395
[Abstract] [Full Text] [Related]
11. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
Stamatoullas A, Fruchart C, Bastit D, Boulet D, Moncondult M, Piguet H, Tilly H.
Cancer; 1996 Jun 01; 77(11):2302-7. PubMed ID: 8635099
[Abstract] [Full Text] [Related]
12. Randomized comparison of granulocyte colony-stimulating factor versus granulocyte-macrophage colony-stimulating factor plus intensive chemotherapy for peripheral blood stem cell mobilization and autologous transplantation in multiple myeloma.
Arora M, Burns LJ, Barker JN, Miller JS, Defor TE, Olujohungbe AB, Weisdorf DJ.
Biol Blood Marrow Transplant; 2004 Jun 01; 10(6):395-404. PubMed ID: 15148493
[Abstract] [Full Text] [Related]
13. [High-dose chemotherapy supported by peripheral blood stem cells to treat intermediate--and high-grade non-Hodgkin's lymphomas].
Ji Y, Ji S, Ju X.
Zhonghua Zhong Liu Za Zhi; 1996 Nov 01; 18(6):471-5. PubMed ID: 9387307
[Abstract] [Full Text] [Related]
14. High-dose therapy followed by autologous peripheral-blood stem-cell transplantation for patients with Hodgkin's disease and non-Hodgkin's lymphoma using unprimed and granulocyte colony-stimulating factor-mobilized peripheral-blood stem cells.
Nademanee A, Sniecinski I, Schmidt GM, Dagis AC, O'Donnell MR, Snyder DS, Parker PM, Stein AS, Smith EP, Molina A.
J Clin Oncol; 1994 Oct 01; 12(10):2176-86. PubMed ID: 7523609
[Abstract] [Full Text] [Related]
15. High-dose chemotherapy with BUCY or BEAC and unpurged peripheral blood stem cell infusion in patients with low-grade non-Hodgkin's lymphoma.
Weaver CH, Schwartzberg L, Rhinehart S, West J, Zhen B, West WH, Buckner CD.
Bone Marrow Transplant; 1998 Feb 01; 21(4):383-9. PubMed ID: 9509973
[Abstract] [Full Text] [Related]
16. A phase II multicenter trial of high-dose sequential chemotherapy and peripheral blood stem cell transplantation as initial therapy for patients with high-risk non-Hodgkin's lymphoma.
Schenkein DP, Roitman D, Miller KB, Morelli J, Stadtmauer E, Pecora AL, Cassileth P, Fernandez H, Cooper BW, Kutteh L, Lazarus HM.
Biol Blood Marrow Transplant; 1997 Oct 01; 3(4):210-6. PubMed ID: 9360783
[Abstract] [Full Text] [Related]
17. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
Lemoli RM, Visani G, Leopardi G, Motta MR, Rizzi S, Testoni N, Curti A, Tura S.
Bone Marrow Transplant; 1999 Feb 01; 23(3):235-41. PubMed ID: 10084254
[Abstract] [Full Text] [Related]
18. Serial intense chemotherapy combining topotecan, etoposide, carboplatin and cyclophosphamide (TECC) followed by autologous hematopoietic stem cell support in patients with high risk soft tissue sarcoma (STS).
Bernbeck B, Bahci S, Meisel R, Troeger A, Schönberger S, Laws HJ, Kramm C, Wessalowski R, Koscielniak E, Dilloo D, Göbel U.
Klin Padiatr; 2007 Feb 01; 219(6):318-22. PubMed ID: 18050041
[Abstract] [Full Text] [Related]
19. High-dose therapy and autologous stem cell rescue for poor risk and refractory lymphoma: a single centre experience of 123 patients.
Mahendra P, Johnson D, Hood IM, Scott MA, Barker P, Bass G, Jestice HK, Bloxham DM, Boraks P, Wimperis JZ, Baglin TP, Marcus RE.
Bone Marrow Transplant; 1996 Jun 01; 17(6):973-8. PubMed ID: 8807102
[Abstract] [Full Text] [Related]
20. Autologous peripheral blood stem cell transplantation after high dose therapy in patients with advanced lymphomas.
Brice P, Marolleau JP, Dombret H, Lepage E, Baruchel A, Adam M, Miclea JM, Sitthy X, Gisselbrecht C.
Bone Marrow Transplant; 1992 May 01; 9(5):337-42. PubMed ID: 1352162
[Abstract] [Full Text] [Related]
Page: [Next] [New Search]
